Cargando…

A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis

To test the feasibility and efficacy of epirubicin and ifosfamide added to first-line chemotherapy with cisplatin and paclitaxel in a phase II randomised clinical trial. Patients with histologically proven epithelial ovarian cancer were randomly assigned to receive first-line polychemotherapy with c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fruscio, R, Colombo, N, Lissoni, A A, Garbi, A, Fossati, R, Ieda', N, Torri, V, Mangioni, C
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2259172/ https://www.ncbi.nlm.nih.gov/pubmed/18253120 http://dx.doi.org/10.1038/sj.bjc.6604231

Ejemplares similares

Evaluation of the paclitaxel–ifosfamide–cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer
por: Kosmas, C, et al.
Publicado: (2009)

Paclitaxel, ifosfamide, and cisplatin (TIP) as salvage and consolidation chemotherapy for advanced germ cell tumor
por: Kurobe, Masahiro, et al.
Publicado: (2014)

Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours
por: Kosmas, C, et al.
Publicado: (2000)

Salvage Chemotherapy with Cisplatin, Ifosfamide, and Paclitaxel in Aggressive Variant of Metastatic Castration-Resistant Prostate Cancer
por: von Amsberg, Gunhild, et al.
Publicado: (2022)

Efficacy and tolerability of paclitaxel, ifosfamide, and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma
por: Scandurra, Giuseppa, et al.
Publicado: (2015)

Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study
por: Frasci, G, et al.
Publicado: (2006)

Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines.
por: Klaassen, U., et al.
Publicado: (1996)

Induction chemotherapy with paclitaxel, ifosfamide, and cisplatin followed by concurrent chemoradiotherapy for unresectable locally advanced head and neck cancer
por: Chitapanarux, I, et al.
Publicado: (2010)

First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence.
por: Sandercock, J., et al.
Publicado: (1998)

Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the ‘Mario Negri’ Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group
por: Buda, A, et al.
Publicado: (2004)

Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial
por: Stathopoulos, G. P., et al.
Publicado: (2010)

Evaluation of Paclitaxel, Ifosfamide, and Cisplatin (TIP) Regimen on Penile Cancer in Adam Malik Medan: A Single Center 2 Years of Experience
por: Sitompul, Ardiansyah Periadi, et al.
Publicado: (2019)

Multicenter randomized phase III trial of Epirubicin plus Paclitaxel vs Epirubicin followed by Paclitaxel in metastatic breast cancer patients: focus on cardiac safety
por: Baldini, E, et al.
Publicado: (2004)

Radiation Recall Dermatitis after Treatment with Paclitaxel and Cisplatin
por: Baek, Seung Woo, et al.
Publicado: (2012)

Effects of paclitaxel and cisplatin on in vitro ovarian follicle development
por: Kim, Yoon Young, et al.
Publicado: (2019)

HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells
por: Ribeiro, J. R., et al.
Publicado: (2016)

Conservative treatment followed by chemotherapy with doxorubicin and ifosfamide for cervical sarcoma botryoides in young females
por: Zanetta, G, et al.
Publicado: (1999)

Seizure following chemotherapy (paclitaxel and cisplatin) in a patient of carcinoma cervix
por: Dana, Rohitashwa, et al.
Publicado: (2016)

Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.
por: Veldhuis, G. J., et al.
Publicado: (1997)

Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
por: de Jong, Loek A. W., et al.
Publicado: (2023)

Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer.
por: Petrasch, S., et al.
Publicado: (1998)

Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy
por: Goyeneche, Alicia A, et al.
Publicado: (2012)

Paclitaxel and cisplatin combined with intensity-modulated radiotherapy for upper esophageal carcinoma
por: Tu, Lingli, et al.
Publicado: (2013)

Genetic polymorphisms and ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Doxorubicin, paclitaxel, and cisplatin based chemotherapy for the treatment of angiosarcoma: Two case reports
por: Lewcun, Joseph A., et al.
Publicado: (2020)

Paclitaxel–ifosfamide–carboplatin combination chemotherapy regimen in advanced uterine and adnexal malignant mixed Mullerian tumours
por: Kosmas, C, et al.
Publicado: (2011)

Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report
por: Sokolova, Alexandra, et al.
Publicado: (2017)

Efficacy of ifosfamide, dacarbazine, doxorubicin and cisplatin in human sarcoma xenografts.
por: Budach, W., et al.
Publicado: (1994)

Neoadjuvant cisplatin and paclitaxel modulate tumor-infiltrating T cells in patients with cervical cancer
por: Heeren, A. Marijne, et al.
Publicado: (2019)

A phase II trial of paclitaxel and epirubicin in advanced breast cancer
por: Rischin, D, et al.
Publicado: (2000)

Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity.
por: Bokemeyer, C., et al.
Publicado: (1996)

A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial
por: Mead, G M, et al.
Publicado: (2005)

Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer
por: Huang, Chen-Yu, et al.
Publicado: (2020)

Neoadjuvant Ifosfamide and Epirubicin in the Treatment of Malignant Peripheral Nerve Sheath Tumors
por: Hirbe, Angela C., et al.
Publicado: (2017)

Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma
por: Sekine, I, et al.
Publicado: (2004)

Bi-weekly Chemotherapy of Paclitaxel and Cisplatin in Patients with Metastatic or Recurrent Esophageal Cancer
por: Cho, Sang-Hee, et al.
Publicado: (2005)

Piperlongumine Induces Apoptosis and Synergizes with Cisplatin or Paclitaxel in Human Ovarian Cancer Cells
por: Gong, Li-Hua, et al.
Publicado: (2014)

Paclitaxel- and/or cisplatin-induced ocular neurotoxicity: a case report and literature review
por: Li, Ying, et al.
Publicado: (2014)

Synergistic effects of the sesquiterpene lactone, EPD, with cisplatin and paclitaxel in ovarian cancer cells
por: van Haaften, Caroline, et al.
Publicado: (2015)

Cathepsin L-mediated resistance of paclitaxel and cisplatin is mediated by distinct regulatory mechanisms
por: Zhao, Yifan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gjouuhphjtf9m906ur8nn0tvtd